IL22 and graft versus host disease: In graft-versus-host disease (GVHD) patients, oral administration of Bacteroides fragilis increased the levels of short chain fatty acids (SCFAs) and IL-22, as well as the number of regulatory T cells, which may account for the improved tight junction integrity and reduced inflammation (48).